Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + apatinib + gemcitabine/cisplatin for initially unresectable biliary tract cancer
ChiCTR2600132818Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab, Rivoceranib, gemcitabine and cisplatin in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by Tongji Hospital. Primary endpoint: Objective response rate. Started Aug 2025; status: recruiting.
02
Drugs
adebrelimabRivoceranibgemcitabinecisplatin
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600132818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132818.